Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report released on Friday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

NASDAQ APVO opened at $0.22 on Friday. Aptevo Therapeutics has a twelve month low of $0.14 and a twelve month high of $10.80. The stock has a fifty day simple moving average of $0.23 and a 200 day simple moving average of $0.44.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is currently owned by institutional investors and hedge funds.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.